Abstract
Antibody-drug conjugates (ADC) allow the delivery of cytotoxic chemotherapeutic agents to tumors. Two ADC delivering topoisomerase I (TOP1) poisons (Enhertu and Trodelvy) have recently been FDA-approved for Her2- and Trop2-expressing solid tumors. In a recent study, a TOP1-anti B7-H4 ADC was described and shown to be synergistic with a novel PARP1-selective inhibitor. See related article by Kinneer et al., p. 1086.
©2023 American Association for Cancer Research.
Publication types
-
Editorial
-
Research Support, N.I.H., Intramural
-
Comment
MeSH terms
-
Humans
-
Immunoconjugates* / pharmacology
-
Immunoconjugates* / therapeutic use
-
Neoplasms* / drug therapy
-
Poly (ADP-Ribose) Polymerase-1
-
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
-
Topoisomerase I Inhibitors / pharmacology
-
Topoisomerase I Inhibitors / therapeutic use
Substances
-
Topoisomerase I Inhibitors
-
AZD5305
-
Immunoconjugates
-
Poly(ADP-ribose) Polymerase Inhibitors
-
PARP1 protein, human
-
Poly (ADP-Ribose) Polymerase-1